CD45 phosphatase is crucial for human and murine acute myeloid leukemia maintenance through its localization in lipid rafts
Metrics: PDF 784 views | HTML 1232 views | ?
Laetitia Saint-Paul1,2, Chi-Hung Nguyen3, Anne Buffière1,2, Jean-Paul Pais de Barros2,4, Arlette Hammann5, Corinne Landras-Guetta3, Rodolphe Filomenko6, Marie-Lorraine Chrétien1,2,7, Pauline Johnson8, Jean-Noël Bastie1,2,7, Laurent Delva1,2 and Ronan Quéré1,2
1 Inserm UMR866, Université Bourgogne-Franche-Comté, Dijon, France
2 LipSTIC Labex, Dijon, France
3 Institut Curie, PSL Research University, UMR9187–U1196, CNRS-Institut Curie, Inserm, Centre Universitaire, Orsay, France
4 Plateforme de lipidomique, Université Bourgogne-Franche-Comté, Dijon, France
5 Plateforme de cytométrie, Université Bourgogne-Franche-Comté, Dijon, France
6 INRA, UMR1324, Dijon, France
7 Hôpital Universitaire François-Mitterrand, Service d’Hématologie Clinique, Dijon, France
8 Department of Microbiology and Immunology, Life Sciences Institute, University of British Columbia, Vancouver, British Columbia, Canada
Ronan Quéré, email:
Keywords: acute myeloid leukemia, CD45 phosphatase, lipid rafts, hematopoietic cells, oncogenic transformation
Received: July 20, 2016 Accepted: August 20, 2016 Published: August 25, 2016
CD45 is a pan-leukocyte protein with tyrosine phosphatase activity involved in the regulation of signal transduction in hematopoiesis. Exploiting CD45 KO mice and lentiviral shRNA, we prove the crucial role that CD45 plays in acute myeloid leukemia (AML) development and maintenance. We discovered that CD45 does not colocalize with lipid rafts on murine and human non-transformed hematopoietic cells. Using a mouse model, we proved that CD45 positioning within lipid rafts is modified during their oncogenic transformation to AML. CD45 colocalized with lipid rafts on AML cells, which contributes to elevated GM-CSF signal intensity involved in proliferation of leukemic cells. We furthermore proved that the GM-CSF/Lyn/Stat3 pathway that contributes to growth of leukemic cells could be profoundly affected, by using a new plasma membrane disrupting agent, which rapidly delocalized CD45 away from lipid rafts. We provide evidence that this mechanism is also effective on human primary AML samples and xenograft transplantation. In conclusion, this study highlights the emerging evidence of the involvement of lipid rafts in oncogenic development of AML and the targeting of CD45 positioning among lipid rafts as a new strategy in the treatment of AML.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.